The glutamine antagonist 6-diazo-5-oxo-l-norleucine (DON) exhibits remarkable anticancer efficacy; however, its therapeutic potential is hindered by its toxicity to gastrointestinal (GI) tissues. We recently reported the discovery of DRP-104, a tumor-targeted DON prodrug with excellent efficacy and tolerability, which is currently in clinical trials. However, DRP-104 exhibits limited aqueous solubility, and the instability of its isopropyl ester promoiety leads to the formation of an inactive M1-metabolite, reducing overall systemic prodrug exposure. Herein, we aimed to synthesize DON prodrugs with various ester and amide promoieties with improved solubility, GI stability, and DON tumor delivery. Twenty-one prodrugs were synthesized and characterized in stability and pharmacokinetics studies. Of these, P11, tert-butyl-(S)-6-diazo-2-((S)-2-(2-(dimethylamino)acetamido)-3-phenylpropanamido)-5-oxo-hexanoate, showed excellent metabolic stability in plasma and intestinal homogenate, high aqueous solubility, and high tumor DON exposures and preserved the ideal tumor-targeting profile of DRP-104. In conclusion, we report a new generation of glutamine antagonist prodrugs with improved physicochemical and pharmacokinetic attributes.

Department of Organic Chemistry Faculty of Science Charles University Prague 128 00 Czech Republic

Institute of Organic Chemistry and Biochemistry v v i Academy of Sciences of the Czech Republic Prague 160 00 Czech Republic

Zobrazit více v PubMed

Cruzat V.; Macedo Rogero M.; Noel Keane K.; Curi R.; Newsholme P. Glutamine: Metabolism and Immune Function, Supplementation and Clinical Translation. Nutrients 2018, 10 (11), 1564.10.3390/nu10111564. PubMed DOI PMC

Meynial-Denis D.Glutamine: Biochemistry, Physiology, and Clinical Applications; CRC Press: 2017.

Wise D. R.; Thompson C. B. Glutamine addiction: a new therapeutic target in cancer. Trends Biochem. Sci. 2010, 35 (8), 427–33. 10.1016/j.tibs.2010.05.003. PubMed DOI PMC

Tarnowski G. S.; Stock C. C. Effects of combinations of azaserine and of 6-diazo-5-oxo-L-norleucine with purine analogs and other antimetabolites on the growth of two mouse mammary carcinomas. Cancer research 1957, 17 (10), 1033–1039. PubMed

Shelton L. M.; Huysentruyt L. C.; Seyfried T. N. Glutamine targeting inhibits systemic metastasis in the VM-M3 murine tumor model. International journal of cancer 2010, 127 (10), 2478–85. 10.1002/ijc.25431. PubMed DOI PMC

Ovejera A. A.; Houchens D. P.; Catane R.; Sheridan M. A.; Muggia F. M. Efficacy of 6-diazo-5-oxo-L-norleucine and N-[N-gamma-glutamyl-6-diazo-5-oxo-norleucinyl]-6-diazo-5-oxo-norleucine against experimental tumors in conventional and nude mice. Cancer research 1979, 39 (8), 3220–3224. PubMed

Catane R.; Von Hoff D. D.; Glaubiger D. L.; Muggia F. M. Azaserine, DON, and azotomycin: three diazo analogs of L-glutamine with clinical antitumor activity. Cancer treatment reports 1979, 63 (6), 1033–1038. PubMed

Rahman A.; Smith F. P.; Luc P. T.; Woolley P. V. Phase I study and clinical pharmacology of 6-diazo-5-oxo-L-norleucine (DON). Investigational new drugs 1985, 3 (4), 369–74. 10.1007/BF00170760. PubMed DOI

Kovach J. S.; Eagan R. T.; Powis G.; Rubin J.; Creagan E. T.; Moertel C. G. Phase I and pharmacokinetic studies of DON. Cancer treatment reports 1981, 65 (11–12), 1031–1036. PubMed

Sullivan M. P.; Nelson J. A.; Feldman S.; Van Nguyen B. Pharmacokinetic and phase I study of intravenous DON (6-diazo-5-oxo-L-norleucine) in children. Cancer chemotherapy and pharmacology 1988, 21 (1), 78–84. 10.1007/BF00262746. PubMed DOI

Sklaroff R. B.; Casper E. S.; Magill G. B.; Young C. W. Phase I study of 6-diazo-5-oxo-L-norleucine (DON). Cancer treatment reports 1980, 64 (12), 1247–1251. PubMed

Lynch G.; Kemeny N.; Casper E. Phase II evaluation of DON (6-diazo-5-oxo-L-norleucine) in patients with advanced colorectal carcinoma. American journal of clinical oncology 1982, 5 (5), 541–3. 10.1097/00000421-198210000-00014. PubMed DOI

Earhart R. H.; Koeller J. M.; Davis H. L. Phase I trial of 6-diazo-5-oxo-L-norleucine (DON) administered by 5-day courses. Cancer treatment reports 1982, 66 (5), 1215–1217. PubMed

Earhart R. H.; Amato D. J.; Chang A. Y.-C.; Borden E. C.; Shiraki M.; Dowd M. E.; Comis R. L.; Davis T. E.; Smith T. J. Phase II trial of 6-diazo-5-oxo-L-norleucine versus aclacinomycin-A in advanced sarcomas and mesotheliomas. Investigational new drugs 1990, 8 (1), 113–119. 10.1007/BF00216936. PubMed DOI

Eagan R. T.; Frytak S.; Nichols W. C.; Creagan E. T.; Ingle J. N. Phase II study on DON in patients with previously treated advanced lung cancer. Cancer treatment reports 1982, 66 (8), 1665–1666. PubMed

Magill G. B.; Myers W. P.; Reilly H. C.; Putnam R. C.; Magill J. W.; Sykes M. P.; Escher G. C.; Karnofsky D. A.; Burchenal J. H. Pharmacological and initial therapeutic observations on 6-diazo-5-oxo-1-norleucine (DON) in human neoplastic disease. Cancer 1957, 10 (6), 1138–50. 10.1002/1097-0142(195711/12)10:6<1138::AID-CNCR2820100608>3.0.CO;2-K. PubMed DOI

Sullivan M. P.; Beatty E. C. Jr.; Hyman C. B.; Murphy M. L.; Pierce M. I.; Severo N. C. A comparison of the effectiveness of standard dose 6-mercaptopurine, combination 6-mercaptopurine and DON, and high-loading 6-mercaptopurine therapies in treatment of the acute leukemias of childhood: results of a coperative study. Cancer chemotherapy reports 1962, 18, 83–95. PubMed

Rais R.; Jančařík A.; Tenora L.; Nedelcovych M.; Alt J.; Englert J.; Rojas C.; Le A.; Elgogary A.; Tan J.; Monincová L.; Pate K.; Adams R.; Ferraris D.; Powell J.; Majer P.; Slusher B. S. Discovery of 6-Diazo-5-oxo-l-norleucine (DON) Prodrugs with Enhanced CSF Delivery in Monkeys: A Potential Treatment for Glioblastoma. Journal of medicinal chemistry 2016, 59 (18), 8621–33. 10.1021/acs.jmedchem.6b01069. PubMed DOI

Tenora L.; Alt J.; Dash R. P.; Gadiano A. J.; Novotná K.; Veeravalli V.; Lam J.; Kirkpatrick Q. R.; Lemberg K. M.; Majer P.; Rais R.; Slusher B. S. Tumor-Targeted Delivery of 6-Diazo-5-oxo-l-norleucine (DON) Using Substituted Acetylated Lysine Prodrugs. Journal of medicinal chemistry 2019, 62 (7), 3524–3538. 10.1021/acs.jmedchem.8b02009. PubMed DOI PMC

Hanaford A. R.; Alt J.; Rais R.; Wang S. Z.; Kaur H.; Thorek D. L. J.; Eberhart C. G.; Slusher B. S.; Martin A. M.; Raabe E. H. Orally bioavailable glutamine antagonist prodrug JHU-083 penetrates mouse brain and suppresses the growth of MYC-driven medulloblastoma. Translational oncology 2019, 12 (10), 1314–1322. 10.1016/j.tranon.2019.05.013. PubMed DOI PMC

Oh M. H.; Sun I. H.; Zhao L.; Leone R. D.; Sun I. M.; Xu W.; Collins S. L.; Tam A. J.; Blosser R. L.; Patel C. H.; Englert J. M.; Arwood M. L.; Wen J.; Chan-Li Y.; Tenora L.; Majer P.; Rais R.; Slusher B. S.; Horton M. R.; Powell J. D. Targeting glutamine metabolism enhances tumor-specific immunity by modulating suppressive myeloid cells. J. Clin. Invest. 2020, 130 (7), 3865–3884. 10.1172/JCI131859. PubMed DOI PMC

Yamashita A. S.; da Costa Rosa M.; Stumpo V.; Rais R.; Slusher B. S.; Riggins G. J. The glutamine antagonist prodrug JHU-083 slows malignant glioma growth and disrupts mTOR signaling. Neuro-oncology advances 2021, 3 (1), vdaa149.10.1093/noajnl/vdaa149. PubMed DOI PMC

Chen J.; Wang R.; Liu Z.; Fan J.; Liu S.; Tan S.; Li X.; Li B.; Yang X. Unbalanced Glutamine Partitioning between CD8T Cells and Cancer Cells Accompanied by Immune Cell Dysfunction in Hepatocellular Carcinoma. Cells 2022, 11 (23), 3924.10.3390/cells11233924. PubMed DOI PMC

Leone R. D.; Zhao L.; Englert J. M.; Sun I. M.; Oh M. H.; Sun I. H.; Arwood M. L.; Bettencourt I. A.; Patel C. H.; Wen J.; Tam A.; Blosser R. L.; Prchalova E.; Alt J.; Rais R.; Slusher B. S.; Powell J. D. Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion. Science (New York, N.Y.) 2019, 366 (6468), 1013–1021. 10.1126/science.aav2588. PubMed DOI PMC

Rais R.; Lemberg K. M.; Tenora L.; Arwood M. L.; Pal A.; Alt J.; Wu Y.; Lam J.; Aguilar J. M. H.; Zhao L.; Peters D. E.; Tallon C.; Pandey R.; Thomas A. G.; Dash R. P.; Seiwert T.; Majer P.; Leone R. D.; Powell J. D.; Slusher B. S. Discovery of DRP-104, a tumor-targeted metabolic inhibitor prodrug. Science advances 2022, 8 (46), eabq592510.1126/sciadv.abq5925. PubMed DOI PMC

Yokoyama Y.; Estok T. M.; Wild R. Sirpiglenastat (DRP-104) Induces Antitumor Efficacy through Direct, Broad Antagonism of Glutamine Metabolism and Stimulation of the Innate and Adaptive Immune Systems. Molecular cancer therapeutics 2022, 21 (10), 1561–1572. 10.1158/1535-7163.MCT-22-0282. PubMed DOI

Johnson M. L.; Doroshow D. B.; Seiwert T. Y.; Gibson M. K.; Velcheti V.; Lisberg A. E.; Patel S. A.; Scheffler M.; Lafleur F.; Dugan M. H.; Sharma S. Phase 1 and phase 2a, first-in-human (FIH) study, of DRP-104, a broad glutamine antagonist, in adult patients with advanced solid tumors. Journal of clinical oncology 2021, 39, TPS3149.10.1200/JCO.2021.39.15_suppl.TPS3149. DOI

Johnson M. L.; Doroshow D. B.; Seiwert T. Y.; Gibson M. K.; Velcheti V.; Lisberg A. E.; Patel S. A.; Scheffler M.; Lafleur F.; Dugan M. H.; Sharma S. Phase 1 and phase 2a, first-in-human (FIH) study, of DRP-104, a broad glutamine antagonist, in adult patients with advanced solid tumors. Journal of Clinical Oncology 2021, 39 (15_suppl), TPS3149.10.1200/JCO.2021.39.15_suppl.TPS3149. DOI

Zangaglia R.; Stocchi F.; Sciarretta M.; Antonini A.; Mancini F.; Guidi M.; Martignoni E.; Pacchetti C. Clinical experiences with levodopa methylester (melevodopa) in patients with Parkinson disease experiencing motor fluctuations: an open-label observational study. Clinical neuropharmacology 2010, 33 (2), 61–6. 10.1097/WNF.0b013e3181c5e60c. PubMed DOI

Davies R. O.; Gomez H. J.; Irvin J. D.; Walker J. F. An overview of the clinical pharmacology of enalapril. British journal of clinical pharmacology 1984, 18 (S2), 215S–229S. 10.1111/j.1365-2125.1984.tb02601.x. PubMed DOI PMC

Davies R. O.; Gomez H. J.; Irvin J. D.; Walker J. F. An overview of the clinical pharmacology of enalapril. Br. J. Clin. Pharmacol. 1984, 18 (S2), 215S–229S. 10.1111/j.1365-2125.1984.tb02601.x. PubMed DOI PMC

Mackman R. L.; Ray A. S.; Hui H. C.; Zhang L.; Birkus G.; Boojamra C. G.; Desai M. C.; Douglas J. L.; Gao Y.; Grant D.; Laflamme G.; Lin K. Y.; Markevitch D. Y.; Mishra R.; McDermott M.; Pakdaman R.; Petrakovsky O. V.; Vela J. E.; Cihlar T. Discovery of GS-9131: Design, synthesis and optimization of amidate prodrugs of the novel nucleoside phosphonate HIV reverse transcriptase (RT) inhibitor GS-9148. Bioorganic & medicinal chemistry 2010, 18 (10), 3606–17. 10.1016/j.bmc.2010.03.041. PubMed DOI

Davey M. S.; Malde R.; Mykura R. C.; Baker A. T.; Taher T. E.; Le Duff C. S.; Willcox B. E.; Mehellou Y. Synthesis and Biological Evaluation of (E)-4-Hydroxy-3-methylbut-2-enyl Phosphate (HMBP) Aryloxy Triester Phosphoramidate Prodrugs as Activators of Vγ9/Vδ2 T-Cell Immune Responses. Journal of medicinal chemistry 2018, 61 (5), 2111–2117. 10.1021/acs.jmedchem.7b01824. PubMed DOI PMC

Qandil A. M. Prodrugs of nonsteroidal anti-inflammatory drugs (NSAIDs), more than meets the eye: a critical review. International journal of molecular sciences 2012, 13 (12), 17244–74. 10.3390/ijms131217244. PubMed DOI PMC

Ferrara S. J.; Meinig J. M.; Placzek A. T.; Banerji T.; McTigue P.; Hartley M. D.; Sanford-Crane H. S.; Banerji T.; Bourdette D.; Scanlan T. S. Ester-to-amide rearrangement of ethanolamine-derived prodrugs of sobetirome with increased blood-brain barrier penetration. Bioorganic & medicinal chemistry 2017, 25 (10), 2743–2753. 10.1016/j.bmc.2017.03.047. PubMed DOI PMC

Cisar J. S.; Grice C. A.; Jones T. K.; Wang D.-H.; Weber O.; Cravat B. F.; Niphakis M. J.; Cognetta A.; Chang J. W.. Preparation of carbamate compounds as modulators of MAGL and/or ABHD6. WO 2013103973 A1, 2013.

Duysen E. G.; Koentgen F.; Williams G. R.; Timperley C. M.; Schopfer L. M.; Cerasoli D. M.; Lockridge O. Production of ES1 plasma carboxylesterase knockout mice for toxicity studies. Chemical research in toxicology 2011, 24 (11), 1891–8. 10.1021/tx200237a. PubMed DOI PMC

Li B.; Sedlacek M.; Manoharan I.; Boopathy R.; Duysen E. G.; Masson P.; Lockridge O. Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma. Biochem. Pharmacol. 2005, 70 (11), 1673–1684. 10.1016/j.bcp.2005.09.002. PubMed DOI

Alt J.; Gori S. S.; Lemberg K. M.; Pal A.; Veeravalli V.; Wu Y.; Aguilar J. M. H.; Dash R. P.; Tenora L.; Majer P.; Sun Q.; Slusher B. S.; Rais R. Glutamine Antagonist GA-607 Causes a Dramatic Accumulation of FGAR which can be used to Monitor Target Engagement. Current drug metabolism 2021, 22 (9), 735–745. 10.2174/1389200222666210831125041. PubMed DOI PMC

Lemberg K. M.; Zhao L.; Wu Y.; Veeravalli V.; Alt J.; Aguilar J. M. H.; Dash R. P.; Lam J.; Tenora L.; Rodriguez C.; Nedelcovych M. T.; Brayton C.; Majer P.; Blakeley J. O.; Rais R.; Slusher B. S. The Novel Glutamine Antagonist Prodrug JHU395 Has Antitumor Activity in Malignant Peripheral Nerve Sheath Tumor. Molecular cancer therapeutics 2020, 19 (2), 397–408. 10.1158/1535-7163.MCT-19-0319. PubMed DOI PMC

Tenora L.; Alt J.; Dash R. P.; Gadiano A. J.; Novotna K.; Veeravalli V.; Lam J.; Kirkpatrick Q. R.; Lemberg K. M.; Majer P.; Rais R.; Slusher B. S. Tumor-Targeted Delivery of 6-Diazo-5-oxo-l-norleucine (DON) Using Substituted Acetylated Lysine Prodrugs. Journal of medicinal chemistry 2019, 62 (7), 3524–3538. 10.1021/acs.jmedchem.8b02009. PubMed DOI PMC

Gharpure S. J.; Nanda L. N.; Kumari D. Enantiospecific Total Synthesis of (+)-3-epi-Epohelmin A Using a Nitrogen-Substituted Donor-Acceptor Cyclopropane. Eur. J. Org. Chem. 2017, 2017 (27), 3917–3920. 10.1002/ejoc.201700498. DOI

Zaminer J.; Brockmann C.; Huy P.; Opitz R.; Reuter C.; Beyermann M.; Freund C.; Müller M.; Oschkinat H.; Kühne R.; Schmalz H. G. Addressing protein-protein interactions with small molecules: a Pro-Pro dipeptide mimic with a PPII helix conformation as a module for the synthesis of PRD-binding ligands. Angewandte Chemie (International ed. in English) 2010, 49 (39), 7111–5. 10.1002/anie.201001739. PubMed DOI

Chiha S.; Soicke A.; Barone M.; Müller M.; Bruns J.; Opitz R.; Neudörfl J.-M.; Kühne R.; Schmalz H.-G. Design and Synthesis of Building Blocks for PPII-Helix Secondary-Structure Mimetics: A Stereoselective Entry to 4-Substituted 5-Vinylprolines. Eur. J. Org. Chem. 2018, 2018 (4), 455–460. 10.1002/ejoc.201701584. DOI

Calimsiz S.; Lipton M. A. Synthesis of N-Fmoc-(2S,3S,4R)-3,4-dimethylglutamine: An application of lanthanide-catalyzed transamidation. Journal of organic chemistry 2005, 70 (16), 6218–21. 10.1021/jo050518r. PubMed DOI PMC

Pal A.; Gori S.; Yoo S. W.; Thomas A. G.; Wu Y.; Friedman J.; Tenora L.; Bhasin H.; Alt J.; Haughey N.; Slusher B. S.; Rais R. Discovery of Orally Bioavailable and Brain-Penetrable Prodrugs of the Potent nSMase2 Inhibitor DPTIP. Journal of medicinal chemistry 2022, 65 (16), 11111–11125. 10.1021/acs.jmedchem.2c00562. PubMed DOI PMC

Thakare R.; Chhonker Y. S.; Gautam N.; Alamoudi J. A.; Alnouti Y. Quantitative analysis of endogenous compounds. J. Pharm. Biomed. Anal. 2016, 128, 426–437. 10.1016/j.jpba.2016.06.017. PubMed DOI

Zimmermann S. C.; Tichý T.; Vávra J.; Dash R. P.; Slusher C. E.; Gadiano A. J.; Wu Y.; Jančařík A.; Tenora L.; Monincová L.; Prchalová E.; Riggins G. J.; Majer P.; Slusher B. S.; Rais R. N-Substituted Prodrugs of Mebendazole Provide Improved Aqueous Solubility and Oral Bioavailability in Mice and Dogs. Journal of medicinal chemistry 2018, 61 (9), 3918–3929. 10.1021/acs.jmedchem.7b01792. PubMed DOI